The latest chatter on Sarepta's (SRPT -3.7%) etiplirsen: Edison Investment Research's Jason...

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

The latest chatter on Sarepta's (SRPT -3.7%) etiplirsen: Edison Investment Research's Jason Zhang notes that the FDA is now "squarely in the middle of the bull and bear scenarios" for SRPT and says the regulator will make a decision on the company's NDA application for etiplirsen "likely before the end of the year." By contrast, Leerink Swann said last week the company may "need to run a Phase III trial in 2014."